Latest news and thought leadership
The latest from Deallus pharmaceutical and life science industry experts
National Healthcare Security Administration (NHSA) protocols
On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.
China Pharma Market Access (CPMA)
Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.
George Gu attends DIA meeting in Suzhou
George Gu, Principal and Head of China at Deallus, recently attended the 2023 DIA China Annual Conference where he participated in an expert panel discussion on "Post-Marketing Medical Activities Based on Specialty Drug Pharmacy Management Platform".
Maximise product value through Medical Insights
Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.
Deallus sponsoring and speaking at the Pharma CI EU Conference
We are excited to be sponsoring and speaking at the Pharma CI EU conference, held in Rome on 30-31 March 2023. Julie Munch Khan, COO, and Stephen Small, Senior Principal at Deallus will be joining other Competitive Intelligence experts across Pharma, Biotech and Medical Devices.
Overview of current policy for rare disease in China
For the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.